UK Cutaneous Lymphoma Group Annual Meeting

The UK Cutaneous Lymphoma Group annual meeting runs in May each year, with the aim of providing a platform for all to meet, network, learn from expert speakers, and keep up to date with developments

Life.science.centre.newcastle

Got a question? Contact us: 01296 619 412 conferences@lymphoma-action.org.uk

About the conference

The UK Cutaneous Lymphoma Group annual meeting runs in May each year, with the aim of providing a platform for all to meet, network, learn from expert speakers, and keep up to date with developments. This year the meeting will take place in Newcastle and feature a renowned keynote speaker - Dr Francine Foss from the Yale Cancer Centre in the United States. 

 

About the UK Cutaneous Lymphoma Group (UKCLG)


The United Kingdom Cutaneous Lymphoma Group was formed in 1999 with the aim of bringing together those interested in treating skin lymphomas in the UK.

The UKCLG is primarily focused on providing clinical education, support and networking for clinicians of all kinds working with this patient group, and also supporting clinical trials and working with other groups to support patients affected by these rare tumours.  Membership is open to any UK or Ireland clinician, and consists of dermatologists, oncologists, haematologists, nurse specialists, histopathologists, clinician scientists, psychologists and allied members across the multi-disciplinary team needed to effectively treat this patient group.

About the keynote speaker - Dr Francine Foss


Dr Francine Foss is a world expert in T cell Lymphomas who has pioneered several novel therapies and led a number of national studies. Dr Foss is currently overseeing a national registry for T cell lymphomas and is a founder and co-chairman of the T CELL Forum, the pre-eminent international T cell lymphoma research meeting. She is a founder of the United States Cutaneous Lymphoma Consortium and the Peripheral T cell Consortium. Dr Foss has also been a translational researcher in T cell Lymphomas and currently is collaborating with a number of laboratories at Yale to identify molecular targets in T cell Lymphoma.